ArticleFrontiers in cellular and infection microbiology2018
Cellular Markers of Active Disease and Cure in Different Forms of
Article in Frontiers in cellular and infection microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 20 citations in OpenAlex.
- Case Report: Long-Term Follow-Up of Visceral Leishmaniasis and HIV Coinfected Patients Without Relapse: Lymphoproliferative Response After Stimulation with SolubleMicroorganisms · 2025Article
- Proteomics of plasma-derived extracellular vesicles from human patients identifies biomarkers for monitoring visceral leishmaniasis therapy.Frontiers in immunology · 2025Article
- CD4Frontiers in immunology · 2024Article
- Memory T cells: promising biomarkers for evaluating protection and vaccine efficacy against leishmaniasis.Frontiers in immunology · 2024Review
- A Miniature Biomedical Sensor for Rapid Detection ofBiosensors · 2023Article
- Alignment of multiple metabolomics LC-MS datasets from disparate diseases to reveal fever-associated metabolites.PLoS neglected tropical diseases · 2023Article
- Evaluation of the protective efficacy of a Leishmania protein associated with distinct adjuvants against visceral leishmaniasis and in vitro immunogenicity in human cells.Parasitology research · 2020Article
- A candidate vaccine for human visceral leishmaniasis based on a specific T cell epitope-containing chimeric protein protects mice againstNPJ vaccines · 2020Article
- Biomarkers in Post-kala-azar Dermal Leishmaniasis.Frontiers in cellular and infection microbiology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increased numbers of peripheral blood mononucleocytes (PBMC) and increased IFN-γ secretion following
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.